A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.

ABSTRACT:

SUBMITTER: Wang Y 

PROVIDER: S-EPMC7572410 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature